Adaptimmune Provides Q4 and Full Year 2024 Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Mizuho Reiterates Outperform Rating on Adaptimmune Therapeutics plc (ADAP)
March 20, 2025 11:30 AM EDTMizuho analyst Graig Suvannavejh reiterated an Outperform rating and $1.50 price target on Adaptimmune Therapeutics plc (NASDAQ: ADAP)
The analyst comments "ADAP reported 4Q results, announcing (1) an update on the recent launch of lead asset Tecelra (including the reporting of first revenue of $1.2mn in... More
